Synlogic reaches end of the road for synthetic biology quest after pivotal data disappoint

Syn­log­ic is clos­ing out its 10-year quest in har­ness­ing syn­thet­ic bi­ol­o­gy to cre­ate new ther­a­pies af­ter de­cid­ing that its lead pro­gram is un­like­ly to suc­ceed in a piv­otal study.

The biotech will cease op­er­a­tions and lay off most of its em­ploy­ees — more than 90% — leav­ing on­ly enough staffers to as­sist in wind­ing down the study. The re­main­ing team will al­so help ex­plore strate­gic al­ter­na­tives, in­clud­ing but not lim­it­ed to M&A, as­set deals or out­right dis­so­lu­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.